#Bioretec #Finland #Tampere #RemeOs #Exemption Document

Bioretec Ltd's Rights Issue Announcement

In a significant move for its shareholders, Bioretec Ltd, the Finnish medical device company known for its innovative biodegradable orthopedic implants, has announced a rights issue as part of its strategic growth plan. Announced on May 28, 2025, this rights issue involves the company offering up to 6,156,618 new shares at a subscription price of EUR 1.50 per share. This initiative not only emphasizes the company’s commitment to its existing shareholders but also seeks to raise capital for further expanding its groundbreaking product line.

Exemption Document Release

To facilitate this offering, Bioretec has prepared an exemption document in alignment with the EU Prospectus Regulation. This exemption document outlines the details necessary for existing shareholders to understand their rights and the overall structure of the offering. It has been made available on Bioretec's official website and will also be found on the website of Danske Bank A/S, Finland Branch. An unofficial English translation will also be accessible, catering to international stakeholders.

The rights issue period is set to begin on June 5, 2025, at 9:30 AM Finnish time, and is expected to conclude on June 19, 2025, at 4:00 PM Finnish time. Importantly, the subscription rights associated with this offering are transferrable, allowing for flexibility and encouraging participation from a wider pool of investors. Trading for these rights is slated to occur on the Nasdaq First North Growth Market Finland from June 5 to June 12, 2025.

Strategic Growth Plans

Bioretec is noted for its focus on developing a new generation of biodegradable implants with its RemeOs™ product line. These innovative products, utilizing a magnesium alloy and hybrid composite materials, are designed not only to enhance surgical outcomes but also to improve the healing process significantly. Such advancements could potentially eliminate the need for removal surgeries post-treatment, thereby improving patient outcomes and reducing healthcare costs.

The company has already achieved significant milestones, including market authorization for its RemeOs™ product in the U.S. in March 2023, followed by regulatory approval in Europe with a CE mark received in January 2025. This rights issue aims to further scale production and commercialization efforts to tap into the growing global orthopedic trauma and spine market valued at over $10 billion.

Leadership and Support

The rights issue is strategically managed by Danske Bank A/S and DNB Carnegie Investment Bank AB, serving as Joint Global Coordinators and Bookrunners. Legal counsel is provided by Krogerus Attorneys Ltd and Borenius Attorneys Ltd, ensuring compliance and expert advice throughout the process. Communications surrounding the offering will be supported by Bravura Ltd, enhancing outreach to existing and potential investors.

On June 5, 2025, Bioretec plans to release a recorded investor presentation, providing a detailed overview of the rights issue and answering stakeholder inquiries in English. This presentation will be accessible on Bioretec’s website, allowing shareholders to gain insights into the opportunities the rights issue presents.

Conclusion

With a clear vision for growth and innovation, Bioretec Ltd is poised to strengthen its position in the healthcare sector. By providing shareholders with an opportunity to participate through this rights issue, Bioretec not only emphasizes its commitment to transparency but also sets the stage for advancing its operational goals around the RemeOs™ product line. For existing shareholders and potential investors alike, this moment marks a crucial step in Bioretec's mission to enhance patient care and surgical outcomes through innovative technology. For more information, please visit Bioretec's official site.